R&D channel feed – Endpoints News

R&D channel feed

Bristol Myers details PhIII win in first-line test of Reblozyl for reducing transfusions in early blood cancer patients

3 years ago

BioXcel looks to expand label to at-home use for lead psych drug. Initial data are mixed

3 years ago

Lilly gears up trio of PhIII trials for its oral GLP-1 amid Novo Nordisk, Pfizer competition

3 years ago

Apellis reports PhII ALS fail after stopping open-label extension in April

3 years ago

Mirati’s drug sitravatinib flops PhIII in combo with Opdivo for certain lung cancer

3 years ago

Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial

3 years ago

Eloxx aims to take lead candidate into PhIII for rare disease

3 years ago

FDA delays Sarepta's Duchenne gene therapy decision by a month

3 years ago

Entasis lands first antibiotic approval eight years after spinning out of AstraZeneca

3 years ago

Phathom Pharmaceuticals resubmits NDA for acid blocker, bags $130M+ from offering

3 years ago

PTC cuts gene therapy programs, discloses PhIII fail in Friedreich's ataxia and CFO exit

3 years ago

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

3 years ago

Affimed lays off around 50 staffers as it brings combo NK cell therapy to PhII

3 years ago

An early-stage fail highlights ongoing ALS drug development challenges, despite recent Biogen OK

3 years ago

PhIII win for smoking cessation treatment puts Achieve Life Sciences on path to FDA, jazzes up deal talks

3 years ago

CohBar, Morphogenesis link up in reverse merger of two cancer biotechs

3 years ago

Icosavax pushes forward combo RSV-hMPV vaccine and announces direct stock offering

3 years ago

Roche scraps second mid-stage schizophrenia trial in as many years

3 years ago

One-fifth of late-stage cancer trials changed primary endpoints after trial start, JAMA Network Open study says

3 years ago

Novo Nordisk says oral version of Wegovy also works at reducing weight in a PhIII study

3 years ago

Exclusive: Sanofi's CEO Paul Hudson talks pipeline, M&A, insulin hearings and Dupixent

3 years ago

As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study

3 years ago

Rain Oncology's stock dives after tumor treatment fails a PhIII trial

3 years ago

Emboldened by Dupixent COPD win, Sanofi execs pitch leading immunology's next era

3 years ago

First page Previous page 85 86 878889 90 91 Next page Last page